EA037123B1 - Соединения для лечения спинальной мышечной атрофии - Google Patents

Соединения для лечения спинальной мышечной атрофии Download PDF

Info

Publication number
EA037123B1
EA037123B1 EA201792465A EA201792465A EA037123B1 EA 037123 B1 EA037123 B1 EA 037123B1 EA 201792465 A EA201792465 A EA 201792465A EA 201792465 A EA201792465 A EA 201792465A EA 037123 B1 EA037123 B1 EA 037123B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrido
pyrimidin
dimethoxyphenyl
methoxyphenyl
fluoro
Prior art date
Application number
EA201792465A
Other languages
English (en)
Russian (ru)
Other versions
EA201792465A1 (ru
Inventor
Соонгиу Чой
Амал Дакка
Гари Митчелл Карп
Яна Нарасимхан
Николай Нарышкин
Энтони А. Турпофф
Марла Л. Виталл
Эллен Уэлч
Мэттью Г. Волл
Тяньлэ Ян
Наньцзин Чжан
Сяоянь Чжан
Синь Чжао
Люк Грин
Эммануэль Пинар
Хасан Ратни
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48948163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA037123(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК., Ф. Хоффманн-Ля Рош Аг filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of EA201792465A1 publication Critical patent/EA201792465A1/ru
Publication of EA037123B1 publication Critical patent/EA037123B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
EA201792465A 2012-02-10 2013-02-08 Соединения для лечения спинальной мышечной атрофии EA037123B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261597523P 2012-02-10 2012-02-10

Publications (2)

Publication Number Publication Date
EA201792465A1 EA201792465A1 (ru) 2018-08-31
EA037123B1 true EA037123B1 (ru) 2021-02-09

Family

ID=48948163

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201792465A EA037123B1 (ru) 2012-02-10 2013-02-08 Соединения для лечения спинальной мышечной атрофии
EA201491505A EA029542B1 (ru) 2012-02-10 2013-02-08 ПРОИЗВОДНЫЕ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201491505A EA029542B1 (ru) 2012-02-10 2013-02-08 ПРОИЗВОДНЫЕ 4Н-ПИРИДО[1,2-а]ПИРИМИДИН-4-ОНА ДЛЯ ЛЕЧЕНИЯ СПИНАЛЬНОЙ МЫШЕЧНОЙ АТРОФИИ

Country Status (29)

Country Link
US (6) US9586955B2 (enExample)
EP (2) EP2812004B1 (enExample)
JP (2) JP6092897B2 (enExample)
KR (2) KR102341596B1 (enExample)
CN (3) CN104349777B (enExample)
AR (1) AR092794A1 (enExample)
AU (2) AU2013216870B2 (enExample)
BR (1) BR112014019750B1 (enExample)
CA (1) CA2863874C (enExample)
CL (1) CL2014002100A1 (enExample)
CO (1) CO7061082A2 (enExample)
CR (1) CR20140376A (enExample)
DK (1) DK2812004T3 (enExample)
EA (2) EA037123B1 (enExample)
EC (1) ECSP14017269A (enExample)
ES (1) ES2697174T3 (enExample)
HU (1) HUE039779T2 (enExample)
IL (2) IL233959A (enExample)
MA (1) MA35920B1 (enExample)
MX (2) MX354074B (enExample)
NZ (1) NZ628186A (enExample)
PE (1) PE20142364A1 (enExample)
PH (2) PH12018501711B1 (enExample)
PL (1) PL2812004T3 (enExample)
SG (2) SG10201609188WA (enExample)
TR (1) TR201813877T4 (enExample)
TW (2) TWI585085B (enExample)
UA (1) UA116981C2 (enExample)
WO (1) WO2013119916A2 (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10327940B2 (en) 2008-11-09 2019-06-25 3D Systems, Inc. Spiral brace
WO2013101974A1 (en) 2011-12-30 2013-07-04 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
EP2809322B9 (en) 2012-01-26 2019-10-30 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
ES2697174T3 (es) * 2012-02-10 2019-01-22 Ptc Therapeutics Inc Compuestos para tratar atrofia muscular espinal
WO2013130689A1 (en) 2012-03-01 2013-09-06 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
EA028382B1 (ru) 2012-03-23 2017-11-30 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
KR20150098675A (ko) * 2012-12-24 2015-08-28 라모트 앳 텔-아비브 유니버시티 리미티드 넌센스 돌연변이로부터 생긴 유전적 질환을 치료하기 위한 물질 및 이를 확인하는 방법
WO2015024876A2 (en) * 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Screening method
EP3082820B1 (en) * 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
US10882868B2 (en) 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
JP6236173B2 (ja) 2014-05-15 2017-11-22 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 脊髄性筋萎縮症を処置するための化合物
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
BR112017004056A2 (pt) 2014-09-12 2017-12-05 Biogen Ma Inc composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
EP3201339A4 (en) 2014-10-03 2018-09-19 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
EP3224248B1 (en) * 2014-11-01 2021-05-05 Shanghai Fochon Pharmaceutical Co. Ltd Certain protein kinase inhibitors
WO2016111896A1 (en) * 2015-01-05 2016-07-14 Sikorsky Aircraft Corporation Integrated vibration damper for additively manufactured structure and method
JP6749343B2 (ja) * 2015-05-20 2020-09-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 脊髄性筋萎縮症を処置するための化合物
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
KR20220105174A (ko) 2015-10-09 2022-07-26 유니버시티 오브 사우스앰톤 유전자 발현의 조절 및 탈조절된 단백질 발현의 스크리닝
AU2016351919B2 (en) * 2015-11-12 2020-11-12 F. Hoffmann-La Roche Ag Compounds for treating amyotrophic lateral sclerosis
CN108289959B (zh) * 2015-11-12 2021-07-16 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的组合物
JP7071917B2 (ja) 2015-12-09 2022-05-19 カデント セラピューティクス,インコーポレーテッド ヘテロ芳香族nmda受容体モジュレーターおよびその使用
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
KR102488323B1 (ko) 2015-12-10 2023-01-12 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
WO2017106377A1 (en) 2015-12-14 2017-06-22 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
CN108473510B (zh) * 2016-04-28 2021-10-29 豪夫迈·罗氏有限公司 制备2-吡唑并[1,5-a]吡嗪-2-基吡啶并[1,2-a]嘧啶-4-酮的方法
WO2017218884A1 (en) 2016-06-16 2017-12-21 Ionis Pharmaceuticals, Inc. Combinations for the modulation of smn expression
EA201991309A1 (ru) 2016-11-28 2019-11-29 Способы модуляции сплайсинга рнк
EP3558318B1 (en) * 2016-12-22 2023-12-20 Novartis AG Nmda receptor modulators and uses thereof
JP7376471B2 (ja) 2017-06-05 2023-11-08 ピーティーシー セラピューティクス, インコーポレイテッド ハンチントン病を処置するための化合物
EP3638318A4 (en) 2017-06-14 2021-03-17 PTC Therapeutics, Inc. RNA SPLICE MODIFICATION PROCESSES
BR112019027719A2 (pt) * 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
CN111182898B (zh) * 2017-06-28 2024-04-16 Ptc医疗公司 用于治疗亨廷顿氏病的方法
IL272413B (en) 2017-08-04 2022-09-01 Skyhawk Therapeutics Inc Methods and compositions for fusion modulation
KR20240035631A (ko) 2017-08-25 2024-03-15 스톡 테라퓨틱스, 인크. 병태 및 질환 치료용 안티센스 올리고머
EP3684766B1 (en) * 2017-09-22 2025-10-29 F. Hoffmann-La Roche AG Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives
CN120290560A (zh) 2017-10-23 2025-07-11 斯托克制药公司 用于治疗基于无义介导的rna衰变的病况和疾病的反义寡聚体
KR20210005559A (ko) 2018-03-27 2021-01-14 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
WO2019213525A1 (en) 2018-05-04 2019-11-07 Stoke Therapeutics, Inc. Methods and compositions for treatment of cholesteryl ester storage disease
AU2019294482B2 (en) 2018-06-27 2022-09-01 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
BR112020026637A2 (pt) * 2018-06-27 2021-03-30 Reborna Biosciences, Inc. Agente profilático ou terapêutico para atrofia muscular espinhal
SMT202400286T1 (it) 2018-06-27 2024-09-16 Ptc Therapeutics Inc Composti eterociclici ed eteroarilici per il trattamento della corea di huntington
JOP20210020A1 (ar) 2018-08-03 2021-01-25 Cadent Therapeutics Inc معدلات عطرية غير متجانسة لمستقبل nmda واستخداماتها
CA3108293A1 (en) * 2018-08-07 2020-02-13 The Children's Hospital Of Philadelphia Alternative splicing regulation of gene expression and therapeutic methods
EP3920926A4 (en) 2019-02-05 2022-10-19 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603592B2 (ja) 2019-02-05 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
EP3920928A4 (en) 2019-02-06 2022-09-28 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
WO2021021775A1 (en) 2019-07-31 2021-02-04 Teva Pharmaceuticals International Gmbh Solid state forms of risdiplam and process for preparation thereof
CN110540535B (zh) * 2019-10-23 2020-07-31 上海再启生物技术有限公司 适合放大制备4-(6-氨基吡啶-3-基)取代哌啶的工艺方法
CN111116576A (zh) * 2019-12-01 2020-05-08 北京师范大学 一种喹嗪酮类化合物及其制备方法
KR20220113431A (ko) 2019-12-02 2022-08-12 스톰 테라퓨틱스 리미티드 Mettl3 저해제로서의 폴리헤테로환식 화합물
EP4097092A1 (en) 2020-01-28 2022-12-07 Protego Biopharma, Inc. Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
US20230340498A1 (en) * 2020-02-12 2023-10-26 The Children's Hospital Of Philadelphia Compositions and methods for inducible alternative splicing regulation of gene expression
MX2022010637A (es) 2020-02-28 2023-01-19 Remix Therapeutics Inc Derivados de piridazina para modular el empalme de acidos nucleicos.
AU2021228285A1 (en) 2020-02-28 2022-09-29 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2021174174A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Thiophenyl derivatives useful for modulating nucleic acid splicing
MX2022010684A (es) 2020-02-28 2023-01-19 Remix Therapeutics Inc Amidas heterocíclicas y su uso para modular el empalme.
TW202517787A (zh) 2020-02-28 2025-05-01 美商Ionis製藥公司 用於調節smn2之化合物及方法
US20230167093A1 (en) 2020-04-08 2023-06-01 Remix Therapeutics Inc. Compounds and methods for modulating splicing
CN116096725A (zh) 2020-04-08 2023-05-09 雷密克斯医疗公司 用于调节剪接的化合物和方法
KR20230022409A (ko) 2020-05-11 2023-02-15 스톡 테라퓨틱스, 인크. 병태 및 질환의 치료를 위한 opa1 안티센스 올리고머
WO2022006543A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
CA3183321A1 (en) 2020-07-02 2022-02-06 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2022070071A1 (en) * 2020-09-30 2022-04-07 Janssen Biotech, Inc. Dihydroorotate dehydrogenase inhibitors
CR20230437A (es) 2021-03-17 2023-10-16 Hoffmann La Roche Nuevos derivados de tiazolopirimidinona
WO2023009585A2 (en) 2021-07-28 2023-02-02 Protego Biopharma, Inc. Transthyretin stabilizing compounds
WO2023034836A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
KR20240096913A (ko) 2021-08-30 2024-06-26 레믹스 테라퓨틱스 인크. 스플라이싱 조절을 위한 화합물 및 방법
WO2023034833A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034827A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
KR20240102938A (ko) 2021-08-30 2024-07-03 레믹스 테라퓨틱스 인크. 스플라이싱 조절을 위한 화합물 및 방법
WO2023064879A1 (en) 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
JP2024538096A (ja) * 2021-10-13 2024-10-18 リミックス セラピューティクス インコーポレイテッド 核酸スプライシングを調節するための化合物及び方法
US20250109140A1 (en) 2022-01-05 2025-04-03 Remix Theraputics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
TW202337442A (zh) 2022-01-05 2023-10-01 美商雷密克斯醫療公司 用於調節剪切之化合物及方法
WO2023133225A1 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
AU2024286618A1 (en) * 2023-06-09 2025-10-30 F. Hoffmann-La Roche Ag Inducible gene expression system
CN117263936B (zh) * 2023-11-21 2024-02-23 中国中医科学院医学实验中心 一种咪唑并[1, 2-a]吡啶衍生物及其制备方法和在中枢神经系统渗透性HDAC6抑制药物中的应用
WO2025233837A1 (en) 2024-05-07 2025-11-13 Takeda Pharmaceutical Company Limited 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
WO1993023398A1 (en) * 1992-05-13 1993-11-25 E.I. Du Pont De Nemours And Company Substituted pyrido[1,2-a]pyrimidinone derivatives as fungicides
US6977255B2 (en) * 2000-01-24 2005-12-20 Kinacia Pty. Ltd. Therapeutic morpholino-substituted compounds
WO2011085990A1 (en) * 2010-01-13 2011-07-21 Institut Pasteur Korea Anti - infective pyrido (1,2 -a) pyrimidines

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3558618A (en) * 1968-04-01 1971-01-26 Dow Chemical Co Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
US4342870A (en) 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
JPS56150091A (en) 1980-03-28 1981-11-20 Janssen Pharmaceutica Nv 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture
US5089633A (en) 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
US5726182A (en) 1990-05-02 1998-03-10 Abbott Laboratories Quinolizinone type compounds
JPH11510478A (ja) * 1995-06-06 1999-09-14 アボツト・ラボラトリーズ キノリジノン型化合物
US5869500A (en) 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
US6630488B1 (en) * 1998-09-21 2003-10-07 Biochem Pharma, Inc. Quinolizinones as integrin inhibitors
EP1227084B1 (en) * 1999-10-28 2005-12-14 Trine Pharmaceuticals, Inc. Drug discharge pump inhibitors
WO2002087589A1 (en) * 2001-04-26 2002-11-07 Daiichi Pharmaceutical Co., Ltd. Medicine for inhibiting drug elimination pump
CA2469316A1 (en) 2001-12-07 2003-06-19 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as gsk-3 inhibitors
GB0205281D0 (en) 2002-03-06 2002-04-17 Novartis Ag Organic compounds
WO2004009558A2 (en) 2002-07-24 2004-01-29 Ptc Therapeutics, Inc. Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
EP1636225B1 (en) * 2003-06-20 2010-02-24 Novartis Vaccines and Diagnostics, Inc. Pyridino 1,2-a pyrimidin-4-one compounds as anticancer agents
EP1749004B1 (en) * 2004-05-04 2007-09-19 Warner-Lambert Company LLC Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
WO2006078834A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
WO2008013997A2 (en) 2006-07-27 2008-01-31 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
US8633019B2 (en) 2008-05-27 2014-01-21 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
US8986935B2 (en) 2008-08-13 2015-03-24 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
WO2011050245A1 (en) * 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
EP2501231B1 (en) * 2009-11-20 2016-12-21 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
WO2013101974A1 (en) 2011-12-30 2013-07-04 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
EP2809322B9 (en) 2012-01-26 2019-10-30 PTC Therapeutics, Inc. Compounds for treating spinal muscular atrophy
ES2697174T3 (es) * 2012-02-10 2019-01-22 Ptc Therapeutics Inc Compuestos para tratar atrofia muscular espinal
WO2013130689A1 (en) 2012-03-01 2013-09-06 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
EA028382B1 (ru) 2012-03-23 2017-11-30 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
JP6236173B2 (ja) 2014-05-15 2017-11-22 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 脊髄性筋萎縮症を処置するための化合物
JP6749343B2 (ja) 2015-05-20 2020-09-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft 脊髄性筋萎縮症を処置するための化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
WO1993023398A1 (en) * 1992-05-13 1993-11-25 E.I. Du Pont De Nemours And Company Substituted pyrido[1,2-a]pyrimidinone derivatives as fungicides
US6977255B2 (en) * 2000-01-24 2005-12-20 Kinacia Pty. Ltd. Therapeutic morpholino-substituted compounds
WO2011085990A1 (en) * 2010-01-13 2011-07-21 Institut Pasteur Korea Anti - infective pyrido (1,2 -a) pyrimidines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NING SHAO et al. Synthesis and structure-activity relationship (SAR) study of 4-azabenzoxazole analogues as H3 antagonists. Bioorganic &Medicinal Chemistry Letters, 2012, vol. 22, pp. 2075-2078, реферат, таблица 3, соединения 33, 34, 35 *

Also Published As

Publication number Publication date
ES2697174T3 (es) 2019-01-22
MX2014009696A (es) 2015-01-14
CA2863874C (en) 2021-02-16
US9586955B2 (en) 2017-03-07
EA029542B1 (ru) 2018-04-30
EP2812004B1 (en) 2018-06-27
JP6363744B2 (ja) 2018-07-25
TWI585085B (zh) 2017-06-01
EP3406252A1 (en) 2018-11-28
JP2015508075A (ja) 2015-03-16
JP6092897B2 (ja) 2017-03-08
IL233959A0 (en) 2014-09-30
IL254045B (en) 2019-05-30
AU2017204248A1 (en) 2017-07-13
CN108299314B (zh) 2024-11-26
JP2017122097A (ja) 2017-07-13
MX2022011699A (es) 2022-11-09
WO2013119916A2 (en) 2013-08-15
US9879007B2 (en) 2018-01-30
AR092794A1 (es) 2015-05-06
MA35920B1 (fr) 2014-12-01
PH12018501711A1 (en) 2019-09-23
EA201792465A1 (ru) 2018-08-31
SG10201609188WA (en) 2016-12-29
CR20140376A (es) 2015-01-23
PH12018501711B1 (en) 2023-05-05
KR102137087B1 (ko) 2020-07-24
UA116981C2 (uk) 2018-06-11
EP2812004A4 (en) 2015-11-11
CN108299314A (zh) 2018-07-20
TW201722942A (zh) 2017-07-01
KR20200093066A (ko) 2020-08-04
CA2863874A1 (en) 2013-08-15
BR112014019750B1 (pt) 2020-03-03
WO2013119916A3 (en) 2013-10-24
KR20140121482A (ko) 2014-10-15
TWI629274B (zh) 2018-07-11
US20180105526A1 (en) 2018-04-19
NZ628186A (en) 2016-03-31
US20170129885A1 (en) 2017-05-11
CN104349777B (zh) 2018-05-01
BR112014019750A8 (pt) 2018-01-16
DK2812004T3 (en) 2018-10-15
ECSP14017269A (es) 2015-09-30
IL233959A (en) 2017-11-30
US20240067646A1 (en) 2024-02-29
PH12014501786B1 (en) 2014-11-10
CL2014002100A1 (es) 2015-10-23
EA201491505A1 (ru) 2015-01-30
TW201336842A (zh) 2013-09-16
KR102341596B1 (ko) 2021-12-21
CN119528903A (zh) 2025-02-28
CO7061082A2 (es) 2014-09-19
SG11201404713PA (en) 2014-09-26
EP3406252B1 (en) 2020-05-13
PH12014501786A1 (en) 2014-11-10
AU2013216870A1 (en) 2014-08-28
TR201813877T4 (tr) 2018-11-21
EP2812004A2 (en) 2014-12-17
US20210276999A1 (en) 2021-09-09
IL254045A0 (en) 2017-10-31
US20150005289A1 (en) 2015-01-01
AU2013216870B2 (en) 2017-07-20
AU2017204248B2 (en) 2019-05-30
CN104349777A (zh) 2015-02-11
PL2812004T3 (pl) 2019-01-31
HUE039779T2 (hu) 2019-02-28
BR112014019750A2 (pt) 2017-06-20
US11753407B2 (en) 2023-09-12
MX354074B (es) 2018-02-12
HK1202077A1 (en) 2015-09-18
US10851101B2 (en) 2020-12-01
US20190375750A1 (en) 2019-12-12
PE20142364A1 (es) 2015-01-10

Similar Documents

Publication Publication Date Title
US20240067646A1 (en) Compounds for treating spinal muscular atrophy
EP2797592B1 (en) Compounds for treating spinal muscular atrophy
BR112014016443B1 (pt) Mistura de pó e método de fabricação de um componente sinterizado
HK40005163A (en) Compounds for treating spinal muscular atrophy
HK40005163B (en) Compounds for treating spinal muscular atrophy
HK1202077B (en) Compounds for treating spinal muscular atrophy
HK1202059B (en) Compounds for treating spinal muscular atrophy